Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Crixivan Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Crixivan (indinavir) prior authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Crixivan (indinavir) for VCHCP members, including covered HIV-1 infection, combination therapy, prescriber qualifications, exclusions, contraindications, and dosing.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCrixivan (indinavir) prior authorization
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 28, 2014
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document HIV infection, a regimen containing at least three antiretroviral agents, and a qualified prescriber.
    SourceLink
    POLICY UPDATE CHANGES

    The February 18, 2025 revision added a note that indinavir is rarely used or no longer administered because of poor efficacy and/or toxicity.

    HIV-1 infectionCovered indication
    ≥3 agentsMinimum regimen
    AAHIVM/IDPrescriber qualification
    ExcludedPediatric use

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    48 oz
    Daily water intake

    Coverage Criteria

    Initial Therapy and Prior Authorization

    Coverage requires prior authorization and ALL of the following criteria:

    ALL of the following

    • Crixivan (indinavir) is prescribed for the treatment of HIV infection.
    • Crixivan is prescribed as part of a multidrug antiretroviral regimen containing at least three antiretroviral agents.
    • ONE of the following prescriber requirements

      • Prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification.
      • Prescribed by a physician who is board-certified in Infectious Disease.

    Crixivan use in pediatric patients is investigational and therefore an excluded benefit (see Evidence of Coverage).

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization and Combination Therapy

    Prior authorization is required for Crixivan (indinavir) for the treatment of HIV infection. It must be used as part of a multidrug antiretroviral regimen containing at least three antiretroviral agents.

    • Indication: treatment of HIV infection.
    • Use in combination with at least three antiretroviral agents.
    Documentation Required

    Qualified Prescriber Required

    Crixivan must be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or by a physician board-certified in Infectious Disease.

    • Required prescriber: AAHIVM-certified Immunology Clinic physician or board-certified Infectious Disease physician.

    Clinical Background

    Crixivan (indinavir) is an antiretroviral HIV-1 protease inhibitor. It binds to HIV-1 protease and inhibits cleavage of viral Gag-Pol polyprotein precursors into the functional proteins required to produce infectious HIV. This results in the formation of immature, noninfectious viral particles.

    Definitions

    Crixivan (indinavir)
    MedicationCrixivan (indinavir)
    Drug classAntiretroviral agent and HIV-1 protease inhibitor
    Role in HIV treatmentInhibits HIV-1 protease activity and cleavage of viral Gag-Pol polyprotein precursors, resulting in immature, noninfectious viral particles
    Pediatric use
    PopulationPediatric patients
    Use statusInvestigational
    Coverage statusExcluded benefit under this policy

    Initial Therapy Criteria

    Initial Therapy

    Initial authorization requires all of the following:

    Initial Crixivan authorization

    • HIV indication: The requested treatment is for HIV infection.
    • Combination regimen: Crixivan is included in a multidrug antiretroviral regimen.At least 3 antiretroviral agents
    • Qualified prescriber: The prescriber is an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or a physician boarded in Infectious Disease.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCrixivan (indinavir) prior authorization
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 28, 2014
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document HIV infection, a regimen containing at least three antiretroviral agents, and a qualified prescriber.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsClinical BackgroundDefinitionsInitial Therapy Criteria

    Unsupported block type: documentation

    Denial Risk

    Pediatric Use Excluded

    Crixivan use in pediatric patients is investigational and is an excluded benefit under the Evidence of Coverage (EOC).

    • Pediatric use is not covered.
    • Do not request authorization for pediatric use as a covered benefit.
    Denial Risk

    Contraindicated Use

    Do not use Crixivan when any listed contraindication is present, including hypersensitivity, prohibited concomitant medications, or sildenafil used for pulmonary artery hypertension.

    • Hypersensitivity to indinavir or any component of the formulation.
    • Concurrent use of alfuzosin, alprazolam, amiodarone, cisapride, ergot alkaloids, lovastatin, oral midazolam, pimozide, simvastatin, St. John’s wort, or triazolam.
    • Concurrent sildenafil use for pulmonary artery hypertension, such as Revatio®.